NHL News & Analysis

Legend Biotech (LEGN) Stock Price Target Raised by UBS on NHL Outlook

UBS increased its price target for Legend Biotech (LEGN) reflecting a positive outlook on its NHL therapy development. No specific new price target was provided in the report. The adjustment signifies UBS's confidence in the market potential of LEGN's therapeutic advancements and could influence investor sentiment positively. This change might impact trading volumes as investors react to the report, indicating potential shifts in the stock's market dynamics.